Viewing Study NCT00191035


Ignite Creation Date: 2025-12-24 @ 10:02 PM
Ignite Modification Date: 2025-12-25 @ 7:39 PM
Study NCT ID: NCT00191035
Status: COMPLETED
Last Update Posted: 2006-12-13
First Post: 2005-09-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
Sponsor: Eli Lilly and Company
Organization:

Study Overview

Official Title: Maintenance of Benefit After 8-Week and 52-Week Treatment With Atomoxetine Hydrochloride in Adolescents With ADHD
Status: COMPLETED
Status Verified Date: 2006-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to assess the efficacy, safety and tolerability of atomoxetine administered once daily in the treatment of adolescents with ADHD after 8 weeks and after 52 weeks
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
B4Z-US-LYCD None None View